Cost Effectiveness of Bosentan for Pulmonary Arterial Hypertension: A Systematic Review.

ABSTRACT:

Objectives

Although many studies have reported on the cost-effectiveness of bosentan for treating pulmonary arterial hypertension (PAH), a systematic review of economic evaluations of bosentan is currently lacking. Objective evaluation of current pharmacoeconomic evidence can assist decision makers in determining the appropriate place in therapy of a new medication.

Methods

Systematic literature searches were conducted in English-language databases (MEDLINE, EMBASE, EconLit databases, and the Cochrane Library) and Chinese-language databases (China National Knowledge Infrastructure, WanFang Data, and Chongqing VIP) to identify studies assessing the cost-effectiveness of bosentan for PAH treatments.

Results

A total of 8 published studies were selected for inclusion. Amo

SUBMITTER: You R 

PROVIDER: S-EPMC6276424 | biostudies-literature | 2018

REPOSITORIES: biostudies-literature